Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Gains from Sales and Divestitures (2020 - 2022)

Historic Gains from Sales and Divestitures for Mirum Pharmaceuticals (MIRM) over the last 3 years, with Q4 2022 value amounting to $122464.0.

  • Mirum Pharmaceuticals' Gains from Sales and Divestitures fell 833.05% to $122464.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $122464.0, marking a year-over-year decrease of 833.05%. This contributed to the annual value of $122464.0 for FY2022, which is 833.05% down from last year.
  • According to the latest figures from Q4 2022, Mirum Pharmaceuticals' Gains from Sales and Divestitures is $122464.0, which was down 833.05% from $100194.0 recorded in Q3 2022.
  • In the past 5 years, Mirum Pharmaceuticals' Gains from Sales and Divestitures registered a high of $133593.0 during Q4 2020, and its lowest value of $33396.0 during Q1 2021.
  • Its 3-year average for Gains from Sales and Divestitures is $82567.5, with a median of $83494.0 in 2020.
  • The largest annual percentage gain for Mirum Pharmaceuticals' Gains from Sales and Divestitures in the last 5 years was 0.6% (2022), contrasted with its biggest fall of 833.05% (2022).
  • Quarter analysis of 3 years shows Mirum Pharmaceuticals' Gains from Sales and Divestitures stood at $133593.0 in 2020, then changed by 0.0% to $133593.0 in 2021, then fell by 8.33% to $122464.0 in 2022.
  • Its last three reported values are $122464.0 in Q4 2022, $100194.0 for Q3 2022, and $66796.0 during Q2 2022.